Trinity Biotech
TRIB
22 hedge funds and large institutions have $11.9M invested in Trinity Biotech in 2021 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 7 reducing their positions, and 9 closing their positions.
243% more call options, than puts
Call options by funds: $422K | Put options by funds: $123K
0.04% less ownership
Funds ownership: 1.36% → 1.32% (-0.04%)
24% less funds holding
Funds holding: 29 → 22 (-7)
28% less capital invested
Capital invested by funds: $16.6M → $11.9M (-$4.74M)
29% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 7
78% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$151K |
| 2 |
HAIM
Hunter Associates Investment Management
Pittsburgh,
Pennsylvania
|
+$94.3K |
| 3 |
LPL Financial
San Diego,
California
|
+$68K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$40.3K |
| 5 |
GSC
Ground Swell Capital
Folly Beach,
South Carolina
|
+$25.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$242K |
| 2 |
NA
Navellier & Associates
Reno,
Nevada
|
-$200K |
| 3 |
SFI
Susquehanna Fundamental Investments
Bala Cynwyd,
Pennsylvania
|
-$98K |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$48.9K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$40K |
TRIB Hedge Fund Activity: Q3 2021 in Review
22 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Trinity Biotech (TRIB) for Q3 2021, worth a combined $11.9M — down 28% from $16.6M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of TRIB and 2 opened new positions — a net loss of 7 holders — while 7 trimmed existing stakes and 5 added.
The largest buyer was Millennium Management, opening a new position worth an estimated $151K. The largest seller was Renaissance Technologies, cutting an estimated $242K.
- 22 institutional investors held Trinity Biotech (TRIB) as of Q3 2021, down from 29 in Q2 2021.
- Funds reported $11.9M of Trinity Biotech stock for Q3 2021, down 28% quarter-over-quarter.
- 2 funds opened new Trinity Biotech positions in Q3 2021 and 9 closed out, a net change of -7 holders.
- The largest Trinity Biotech buyer in Q3 2021 was Millennium Management, an estimated $151K added.
- The largest Trinity Biotech seller in Q3 2021 was Renaissance Technologies, an estimated $242K sold.
Based on aggregated 13F filings for Q3 2021.